Cargando…
Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659801/ https://www.ncbi.nlm.nih.gov/pubmed/31384388 http://dx.doi.org/10.18632/oncotarget.27081 |
| _version_ | 1783439202183020544 |
|---|---|
| author | Luen, Stephen L. Salgado, Roberto Loi, Sherene |
| author_facet | Luen, Stephen L. Salgado, Roberto Loi, Sherene |
| author_sort | Luen, Stephen L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6659801 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-66598012019-08-05 Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy Luen, Stephen L. Salgado, Roberto Loi, Sherene Oncotarget Editorial Impact Journals LLC 2019-07-23 /pmc/articles/PMC6659801/ /pubmed/31384388 http://dx.doi.org/10.18632/oncotarget.27081 Text en Copyright: © 2019 Luen et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Editorial Luen, Stephen L. Salgado, Roberto Loi, Sherene Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy |
| title | Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy |
| title_full | Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy |
| title_fullStr | Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy |
| title_full_unstemmed | Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy |
| title_short | Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy |
| title_sort | residual disease and immune infiltration as a new surrogate endpoint for tnbc post neoadjuvant chemotherapy |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659801/ https://www.ncbi.nlm.nih.gov/pubmed/31384388 http://dx.doi.org/10.18632/oncotarget.27081 |
| work_keys_str_mv | AT luenstephenl residualdiseaseandimmuneinfiltrationasanewsurrogateendpointfortnbcpostneoadjuvantchemotherapy AT salgadoroberto residualdiseaseandimmuneinfiltrationasanewsurrogateendpointfortnbcpostneoadjuvantchemotherapy AT loisherene residualdiseaseandimmuneinfiltrationasanewsurrogateendpointfortnbcpostneoadjuvantchemotherapy |